Latest Financials News

Magnetic Resources NL’s Feasibility Study confirms a robust standalone development for its Lady Julie Gold Project in Western Australia, projecting over 1 million ounces of gold production across nine years with strong financial returns.

Aurum Resources reports strong high-grade drilling results at its Boundiali and Napié gold projects, backed by a $35.6 million strategic placement to fund resource expansion and feasibility studies.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Bastion Minerals and former advisor GTT Ventures have resolved their legal dispute, leading to the withdrawal of a writ that had cast uncertainty over the company.

Spartan Resources Limited shares have been suspended from the ASX following court approval of a scheme of arrangement for its acquisition by Ramelius Resources Limited. This marks a significant step toward the consolidation of gold mining assets in Western Australia.

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

WAM Global Limited has updated its special fully franked dividend and clarified the Dividend Reinvestment Plan price for the six months ending December 2024, offering investors a clear view on income and reinvestment options.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Amotiv Limited reports a slight decline in EBITA for FY25 alongside a significant non-cash impairment on its APG business, reflecting a cautious outlook amid challenging market conditions.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.